215 related articles for article (PubMed ID: 1405328)
1. Effect of dialyzer geometry during hemodialysis with cuprophane membranes.
Taylor JE; McLaren M; Mactier RA; Henderson IS; Stewart WK; Belch JJ
Kidney Int; 1992 Aug; 42(2):442-7. PubMed ID: 1405328
[TBL] [Abstract][Full Text] [Related]
2. Patient reactions and granulocyte degranulation during hemodialysis with cuprophane and polycarbonate membranes. A double-blind study.
Danielson BG; Hällgren R; Venge P
Blood Purif; 1986; 4(1-3):147-50. PubMed ID: 3524607
[TBL] [Abstract][Full Text] [Related]
3. Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients.
Taylor JE; Belch JJ; McLaren M; Henderson IS; Stewart WK
Kidney Int; 1993 Jul; 44(1):182-90. PubMed ID: 8355460
[TBL] [Abstract][Full Text] [Related]
4. Hemodialysis-associated platelet loss: study of the relative contribution of dialyzer membrane composition and geometry.
Docci D; Turci F; Del Vecchio C; Bilancioni R; Cenciotti L; Pretolani E
Int J Artif Organs; 1984 Nov; 7(6):337-40. PubMed ID: 6526528
[TBL] [Abstract][Full Text] [Related]
5. The influence of dialyzer geometry on blood coagulation and biocompatibility.
Lins LE; Boberg U; Jacobson SH; Kjellstrand C; Ljungberg B; Skröder R
Clin Nephrol; 1993 Nov; 40(5):281-5. PubMed ID: 8281717
[TBL] [Abstract][Full Text] [Related]
6. Effect of dialyzer geometry on granulocyte and complement activation.
Schaefer RM; Heidland A; Hörl WH
Am J Nephrol; 1987; 7(2):121-6. PubMed ID: 3496792
[TBL] [Abstract][Full Text] [Related]
7. [Changes in leukocyte counts using a cellulose acetate membrane (FB-T) during hemodialysis. A comparison with a cuprophane membrane].
Pak K; Kobira S; Tomoyoshi T; Nishimura N
Hinyokika Kiyo; 1986 Sep; 32(9):1231-5. PubMed ID: 3812143
[TBL] [Abstract][Full Text] [Related]
8. Intradialytic body weight changes and dialyzer pore size as main contributing factors to the evolution of beta-2-microglobulin in dialysis.
Vanholder RC; Ringoir SM
Blood Purif; 1990; 8(1):32-44. PubMed ID: 2198890
[TBL] [Abstract][Full Text] [Related]
9. Soluble P-selectin during a single hemodialysis session in patients with chronic renal failure and erythropoietin treatment.
Stasko J; Galajda P; Ivanková J; Hollý P; Rozborilová E; Kubisz P
Clin Appl Thromb Hemost; 2007 Oct; 13(4):410-5. PubMed ID: 17911193
[TBL] [Abstract][Full Text] [Related]
10. Hemodialysis-associated platelet activation and thrombocytopenia.
Hakim RM; Schafer AI
Am J Med; 1985 Apr; 78(4):575-80. PubMed ID: 3885730
[TBL] [Abstract][Full Text] [Related]
11. Biocompatible dialysis membranes and oxidative stress in patients wih end-stage renal disease on maintenance haemodialysis.
Abdel-Naeem NM; Kandell NF; El-Shamaa AA; Harba TM; Abdel-Hady AA
J Egypt Soc Parasitol; 2005 Dec; 35(3 Suppl):1173-97. PubMed ID: 16363293
[TBL] [Abstract][Full Text] [Related]
12. [Beneficial effect of AN69 membranes on anemia in hemodialyzed patients].
García Cortés MJ; Sánchez Perales MC; Liébana A; Gil JM; Borrego FJ; Borrego J; Pérez del Barrio P; Serrano P; Pérez Bañasco V
Nefrologia; 2001; 21(4):370-5. PubMed ID: 11816513
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of platelets and hemostasis during hemodialysis with six different membranes.
Verbeelen D; Jochmans K; Herman AG; Van der Niepen P; Sennesael J; De Waele M
Nephron; 1991; 59(4):567-72. PubMed ID: 1766495
[TBL] [Abstract][Full Text] [Related]
14. Influence of acetate and bicarbonate hemodialysis on the plasma erythropoietin concentration in patients with chronic renal failure.
Wiecek A; Franek E; Kokot F; Rudka R
Int J Artif Organs; 1997 Feb; 20(2):108-11. PubMed ID: 9093890
[TBL] [Abstract][Full Text] [Related]
15. [Effect of hemodialysis with cuprophane and polysulfone membranes on counts of leukocytes, granulocytes, monocytes, lymphocytes and lymphocyte subsets].
Moczulski D; Zukowska-Szczechowska E; Grzeszczak W; Religa Z; Cichoń R; Szydłowska I
Pol Arch Med Wewn; 1994 Nov; 92(5):400-7. PubMed ID: 7885988
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte activation and adhesion molecules during hemodialysis with cuprophane and a high-flux biocompatible membrane.
Combe C; Pourtein M; de Précigout V; Baquey A; Morel D; Potaux L; Vincendeau P; Bézian JH; Aparicio M
Am J Kidney Dis; 1994 Sep; 24(3):437-42. PubMed ID: 8079969
[TBL] [Abstract][Full Text] [Related]
17. The effect of dialyser membrane material on intradialytic changes in platelet count, platelet aggregation, circulating platelet aggregates and antithrombin III.
Knudsen F; Nielsen AH; Kristensen SD
Scand J Urol Nephrol; 1985; 19(3):227-32. PubMed ID: 4070991
[TBL] [Abstract][Full Text] [Related]
18. Increases in circulating level of platelet-activating factor lag behind transient neutropenia during hemodialysis with cuprophane membranes.
Sakaguchi K; Morimoto S; Chen YH; Nakamoto Y; Ogihara T
Nephron; 1991; 59(3):455-60. PubMed ID: 1758537
[TBL] [Abstract][Full Text] [Related]
19. Citrate anticoagulation does not correct cuprophane bioincompatibility as evaluated by the expression of leukocyte surface molecules.
Dhondt A; Vanholder R; Waterloos MA; Glorieux G; De Smet R; Lameire N
Nephrol Dial Transplant; 1998 Jul; 13(7):1752-8. PubMed ID: 9681723
[TBL] [Abstract][Full Text] [Related]
20. Leucocyte occlusion of cuprophane membranes as a cause of reduced hemodialysis efficiency.
Dodd NJ; Parsons V; Weston MJ
Int J Artif Organs; 1982 Jul; 5(4):275-6. PubMed ID: 7118290
[No Abstract] [Full Text] [Related]
[Next] [New Search]
